Application No. 09/996,438
Filing Date: November 20,2001
Docket No. 5724-03-BHJ

IN THE CLAIMS

1. (Currently amended) A method of interfering with the isolation and conversion of a sympathomimetic amine to other pharmacologically active compounds comprising manufacturing a pharmaceutical composition comprising: an acid salt of a sympathomimetic amine and at least one combination inhibitor, said combination inhibitor ~~is~~ being an amino polymer or a salt of a transition metal, wherein each said combination inhibitor is a single component and is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine and to interfere with the conversion of said sympathomimetic amine to other pharmacologically active compounds without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

Claims 2 – 31 (Cancelled, without prejudice)

32. (Currently amended) The method according to claim 1 wherein said pharmaceutical composition ~~according to claim 1~~ further comprise~~sing~~ at least one reaction inhibitor, wherein said reaction inhibitor is present in amounts sufficient to interfere with the conversion of said sympathomimetic amine to other pharmacologically active compounds without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

33. (Currently amended) The method according to claim 1 wherein said pharmaceutical composition ~~according to claim 1~~ further comprise~~sing~~ at least one separation inhibitor, wherein said separation inhibitor is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine without significantly

altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

34. (Cancelled, without prejudice)

35. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said sympathomimetic amine is selected from the group consisting of pseudoephedrine hydrochloride, pseudoephedrine sulfate, ephedrine hydrochloride and phenylpropanolamine hydrochloride.

36. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 35 wherein said sympathomimetic amine is pseudoephedrine hydrochloride.

37. (currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said other pharmacologically active compound is selected from the group consisting of methamphetamine, amphetamine, methacathinone and cathinone.

38. (Cancelled, without prejudice)

39. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said amino polymer is a copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

40. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 39 wherein said amino polymer is the neutralized hydrochloride salt form of the copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

41. (Currently amended) The method according to claim 1 wherein said composition ~~according to claim 1~~ further comprises~~ing~~ a transition metal is selected from the group consisting of iron, cobalt, copper, chromium, manganese, nickel, zinc and combinations thereof.

42. (Currently amended) The ~~composition~~ method according to claim 41 wherein the anion of said transition metal salt is selected from the group consisting of chloride, oxide, sulfate and gluconate.

43. (Cancelled, without prejudice)

44. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 42 wherein said transition metal salt is selected from the group consisting of ferrous gluconate, zinc gluconate, copper gluconate and combinations thereof.

45. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 32 wherein said reaction inhibitor is selected from the group consisting of water insoluble polyhydroxy compounds, non-polymeric water soluble polyhydroxy compounds, solvent soluble ester compounds and combinations thereof.

46. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 45 wherein said water insoluble polyhydroxy compound is selected from the group consisting of ethylcellulose, cellulose and combinations thereof.

47. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 45 wherein said non-polymeric water soluble polyhydroxy compound is selected from the group consisting of fructose, glycerin, sorbitol, lactitol, mannitol, xylitol, maltitol, galactose and combinations thereof.

48. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 45 wherein said solvent soluble ester is selected from the group consisting of glycerin esters, esters of glycerin polymers, sorbitol esters, propylene glycol esters, polyethylene glycol esters, sucrose esters, esters of ethoxylated fatty alcohols and combinations thereof.

49. (Currently amended) The ~~pharmaceutical composition~~ method according to claim~~s~~ 33 ~~or 34~~ wherein said separation inhibitor is selected from the group consisting of water soluble cellulose compounds, polysaccharide gums, polyethylene oxide polymers, acrylic acid polymers, starches, magnesium aluminum silicates, polyvinylpyrrolidones, clays and combinations thereof.

50. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said amino polymer is from about 1% to about 100% in the neutralized salt form.

51. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said amino polymer is from about 85% to about 98% in the neutralized salt form.

52. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 1 wherein said amino polymer is the neutralized hydrochloride salt form of the copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

53. (Currently amended) The ~~pharmaceutical composition~~ method according to claim 52 wherein said copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate is from about 85% to about 98% in the neutralized hydrochloride salt form.

Application No. 09/996,438
Filing Date: November 20,2001
Docket No. 5724-03-BHJ

54. (New) A method of interfering with the isolation and conversion of a pseudoephedrine to other pharmacologically active compounds comprising manufacturing a pharmaceutical composition comprising: an acid salt of a pseudoephedrine and at least one combination inhibitor, said combination inhibitor being an amino polymer or a salt of a transition metal, wherein each said combination inhibitor is a single component and is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine and to interfere with the conversion of said sympathomimetic amine to other pharmacologically active compounds without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.